Neuro / Head & NeckNews

Donanemab surveillance MRI finds ARIA in one in five patients

Radiology Businesstoday

Real-world MRI surveillance after donanemab: 10 of 48 patients (20.8%) developed ARIA; APOE ε4 carriers were more likely; 15.7% discontinued therapy.

  • Of 48 patients with at least one surveillance MRI after starting donanemab, 10 (20.8%) developed amyloid-related imaging abnormalities (ARIA), including edema/effusions and microhemorrhages.
  • APOE ε4 carriers were significantly more likely to develop ARIA overall and ARIA-H specifically than noncarriers.
  • Eight patients (15.7%) discontinued donanemab, including five due to progressive ARIA.
Read the source

Also covered by

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.